—

Rhythm Pharmaceuticals Inc (RYTM) — the peer cohort

As of 2026-11-18 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Rhythm Pharmaceuticals Inc ranks 7 of 7 in its cohort on the Closelooknet composite (45/100) — the cohort is led by Halozyme Therapeutics Inc at 72/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
RYTM Rhythm Pharmaceuticals Inc 45 82 21 7 info 2.6%
HALO Halozyme Therapeutics Inc 72 69 94 49 info 28.5%
ONC BeOne Medicines AG 66 87 68 29 ok 5%
REGN Regeneron Pharmaceuticals Inc 65 90 73 47 watch 3.4%
ARGX.BR Argen-X 64 77 75 26 ok 7.1%
RIGL Rigel Pharmaceuticals Inc 64 75 89 76 info 19.2%
UCB.BR UCB SA 64 75 71 42 info 5.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-18

Quick answers

Who are Rhythm Pharmaceuticals Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Halozyme Therapeutics Inc (HALO), BeOne Medicines AG (ONC), Regeneron Pharmaceuticals Inc (REGN), Argen-X (ARGX.BR), Rigel Pharmaceuticals Inc (RIGL), UCB SA (UCB.BR), as of 2026-11-18.

How does RYTM score against its peers?

Rhythm Pharmaceuticals Inc's composite reads 45/100, ranking 7 of 7 in its cohort as of 2026-11-18; the cohort's highest composite is Halozyme Therapeutics Inc at 72/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.